BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu YS, Lin CY, Chuang MT, Lin CY, Tsai YS, Wang CK, Ou MC. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. BMC Gastroenterol 2018;18:124. [PMID: 30075752 DOI: 10.1186/s12876-018-0848-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Cao G, Liu Y, Li L, Zhao X, Liu R, Liu J, Liu J, Cao H. A Comparison of Adverse Events Among Radiofrequency Ablation, Conventional Transarterial Chemoembolization (TACE) and Drug-Eluting Bead TACE in Treating Hepatocellular Carcinoma Patients. Cancer Manag Res 2021;13:5373-82. [PMID: 34262345 DOI: 10.2147/CMAR.S308097] [Reference Citation Analysis]
2 Liu C, Li T, He JT, Shao H. TACE combined with microwave ablation therapy vs. TACE alone for treatment of early- and intermediate-stage hepatocellular carcinomas larger than 5 cm: a meta-analysis. Diagn Interv Radiol 2020;26:575-83. [PMID: 32965220 DOI: 10.5152/dir.2020.19615] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Huang Y, Cheng X, Sun P, Li T, Song Z, Zheng Q. Supplementary Sorafenib Therapies for Hepatocellular Carcinoma-A Systematic Review and Meta-Analysis: Supplementary Sorafenib for Liver Cancer. J Clin Gastroenterol 2019;53:486-94. [PMID: 30939505 DOI: 10.1097/MCG.0000000000001175] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Tang J, Huang Z, Xu J, Lv Q, Wang P. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history. Clin Res Hepatol Gastroenterol 2021;:101814. [PMID: 34597848 DOI: 10.1016/j.clinre.2021.101814] [Reference Citation Analysis]
5 Gong X, Huang A. Differential expression and diagnostic significance of P53, MutS homologs 2, tropomyosin-4 in alpha-fetoprotein-negative hepatocellular carcinoma. J Clin Lab Anal 2020;34:e23353. [PMID: 32363617 DOI: 10.1002/jcla.23353] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Bucalau AM, Tancredi I, Verset G. In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play? Cancers (Basel) 2021;13:5129. [PMID: 34680278 DOI: 10.3390/cancers13205129] [Reference Citation Analysis]
7 Liu YS, Lin XZ, Chen CY, Chiu YC, Kang JW, Tsai HW, Hung HY, Ho CM, Ou MC. Safety and effectiveness of new embolization microspheres SCBRM for intermediate-stage hepatocellular carcinoma: A feasibility study. Bosn J Basic Med Sci 2021;21:339-45. [PMID: 32841586 DOI: 10.17305/bjbms.2020.4770] [Reference Citation Analysis]
8 Bi Y, Shi X, Ren J, Yi M, Han X. Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads. Sci Rep 2022;12:8136. [PMID: 35581365 DOI: 10.1038/s41598-022-12334-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Karalli A, Teiler J, Haji M, Seth E, Brismar TB, Wahlin S, Axelsson R, Stål P. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting. Scand J Gastroenterol 2019;54:905-12. [PMID: 31287338 DOI: 10.1080/00365521.2019.1632925] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Bi Y, Shi X, Ren J, Yi M, Han X, Song M. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma. BMC Gastroenterol 2021;21:231. [PMID: 34020608 DOI: 10.1186/s12876-021-01816-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zhao GS, Liu S, Liu Y, Li C, Wang RY, Bian J, Zhang YW, Zhou J, Lin YJ, Wu J. Assessment of efficacy and prognostic factors by Gelfoam for DEB-TACE in unresectable large hepatocellular carcinoma with portal vein tumor thrombus: a multi-center retrospective study. Expert Rev Gastroenterol Hepatol 2022;:1-8. [PMID: 35709813 DOI: 10.1080/17474124.2022.2091545] [Reference Citation Analysis]
12 Bargellini I, Lorenzoni V, Lorenzoni G, Scalise P, Andreozzi G, Bozzi E, Giorgi L, Cervelli R, Scandiffio R, Perrone O, Meccia DV, Boccuzzi A, Daviddi F, Cicorelli A, Lunardi A, Crocetti L, Turchetti G, Cioni R. Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis. Eur Radiol 2021. [PMID: 33871708 DOI: 10.1007/s00330-021-07905-x] [Reference Citation Analysis]
13 Fan W, Guo J, Zhu B, Wang S, Yu L, Huang W, Fan H, Li F, Wu Y, Zhao Y, Wang Y, Xue M, Wang H, Li J. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS. Eur Radiol 2021. [PMID: 33893536 DOI: 10.1007/s00330-021-07834-9] [Reference Citation Analysis]
14 Bie Z, Li Y, Li B, Wang D, Li L, Li X. The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer. Thorac Cancer 2019;10:1770-8. [PMID: 31321919 DOI: 10.1111/1759-7714.13139] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
15 Bi Y, Shi X, Yi M, Han X, Ren J. Pirarubicin-loaded CalliSpheres® drug-eluting beads for the treatment of patients with stage III-IV lung cancer. Acta Radiol 2022;63:311-8. [PMID: 33615822 DOI: 10.1177/0284185121994298] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
16 Hendriks P, Sudiono DR, Schaapman JJ, Coenraad MJ, Tushuizen ME, Takkenberg RB, Oosterveer TTM, de Geus-Oei LF, van Delden OM, Burgmans MC. Thermal ablation combined with transarterial chemoembolization for hepatocellular carcinoma: What is the right treatment sequence? Eur J Radiol 2021;144:110006. [PMID: 34717187 DOI: 10.1016/j.ejrad.2021.110006] [Reference Citation Analysis]
17 Zane KE, Makary MS. Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancers (Basel) 2021;13:5430. [PMID: 34771593 DOI: 10.3390/cancers13215430] [Reference Citation Analysis]
18 Shao G, Zou Y, Lucatelli P, Tsilimigras DI, Shimise S, Kawaguchi T. Chinese expert consensus on technical recommendations for the standard operation of drug-eluting beads for transvascular embolization. Ann Transl Med 2021;9:714. [PMID: 33987412 DOI: 10.21037/atm-21-1678] [Reference Citation Analysis]
19 Wei G, Yang J. Advances in the treatment of hepatocellular carcinoma using drug-eluting beads. J Interv Med 2020;3:122-7. [PMID: 34805921 DOI: 10.1016/j.jimed.2020.07.003] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Chui AMN, Yau TCC, Cheung TT. An overview in management of hepatocellular carcinoma in Hong Kong using the Hong Kong Liver Cancer (HKLC) staging system. Glob Health Med 2020;2:312-8. [PMID: 33330826 DOI: 10.35772/ghm.2020.01062] [Reference Citation Analysis]
21 Pan F, Schneider D, Ryschich E, Qian B, Vollherbst DF, Möhlenbruch MA, Jugold M, Eichwald V, Stenzel P, Pereira PL, Richter GM, Kauczor HU, Sommer CM, Do TD. In Vitro Characterization of a Novel Type of Radiopaque Doxorubicin-Loaded Microsphere. Cardiovasc Intervent Radiol 2020;43:636-47. [PMID: 31965224 DOI: 10.1007/s00270-020-02407-7] [Reference Citation Analysis]